0000000000083525

AUTHOR

Mohamed Bouattour

0000-0002-3919-4135

showing 4 related works from this author

Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study

2022

Background & Aims Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis…

Settore MED/12 - GastroenterologiaCarcinoma HepatocellularHepatologyHepatocellular carcinomaSARS-CoV-2Liver NeoplasmsCOVID-19hepatocellular carcinomamortalityCohort Studiesliver cancerCOVID-19 TestingCross-Sectional Studiesmortality.HumansMortalityLiver cancerRetrospective Studies
researchProduct

Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent

2021

Purpose: The purpose of this study was to compare the value of contrast-enhanced computed tomography (CT) to that of magnetic resonance imaging obtained with extracellular contrast agent (ECA-MRI) for the diagnosis of a tumor capsule in hepatocellular carcinoma (HCC) using histopathologic findings as the standard of reference. Materials and methods: This retrospective study included patients with pathologically-proven resected HCCs with available preoperative contrast-enhanced CT and ECA-MRI examinations. Two blinded radiologists independently reviewed contrast-enhanced CT and ECA-MRI examinations to assess the presence of an enhancing capsule. The histopathological analysis of resected spe…

Gadolinium DTPAMaleCarcinoma HepatocellularContrast MediaComputed tomographySensitivity and SpecificityMcNemar's testExtracellularmedicineHumansRadiology Nuclear Medicine and imagingCapsule Computed tomography Extracellular contrast agent Hepatocellular carcinoma Magnetic resonance imagingAgedRetrospective StudiesRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCapsuleMagnetic resonance imagingRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingHepatocellular carcinomaFemaleTomography X-Ray ComputedSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessNuclear medicineKappaDiagnostic and Interventional Imaging
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS

2021

Background & Aims The histopathological subtypes of hepatocellular carcinoma (HCC) are associated with distinct clinical features and prognoses. This study aims to report Liver Imaging Reporting and Data System (LI-RADS)-defined imaging features of different HCC subtypes in a cohort of resected tumours and to assess the influence of HCC subtypes on computed tomography (CT)/magnetic resonance imaging (MRI) LI-RADS categorisation in the subgroup of high-risk patients. Methods This retrospective institutional review board-approved study included patients with resected HCCs and available histopathological classification. Three radiologists independently reviewed preoperative CT and MRI exams. T…

medicine.medical_specialtyHepatocellular carcinomaALT alanine transaminaseComputed tomographyRC799-869AST aspartate aminotransferaseOS overall survivalHistopathological subtypeMagnetic resonance imagingNOS-HCC not otherwise specified hepatocellular carcinomaInternal MedicinemedicineImmunology and AllergyIn patientComputed tomographyLI-RADS Liver Imaging Reporting and Data SystemLiver imagingHepatologymedicine.diagnostic_testbiologyUS ultrasoundbusiness.industryNot Otherwise SpecifiedGastroenterologyTIV tumour-in-veinMagnetic resonance imagingHBP hepatobiliary phaseDiseases of the digestive system. Gastroenterologymedicine.diseasedigestive system diseasesHistopathological subtypesCT computed tomographyRFS recurrence-free survivalAlanine transaminaseHepatocellular carcinomaSH-HCC steatohepatitic hepatocellular carcinomaCohortMTM-HCC macrotrabecular-massive hepatocellular carcinomabiology.proteinLI-RADSRadiologyAPHE arterial phase hyperenhancementbusinessHCC hepatocellular carcinomaMRI magnetic resonance imagingResearch ArticleJHEP Reports
researchProduct